1. Home
  2. Live Updates
  3. Tiprank best stocks

Live Breaking News & Updates on Tiprank best stocks

Stay informed with the latest breaking news from Tiprank best stocks on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tiprank best stocks and stay connected to the pulse of your community

Lumber prices are up 232% and 'could spiral out of control in the next few months' – TodayHeadline


These 2 Penny Stocks Could Rally Over 100%, Says Oppenheimer
Speaking of economic opportunity, and the general benefits of wide-ranging growth, President John Kennedy once said, “A rising tide lifts all boats.” As the COVID crisis fades, and economic activity starts returning to normal, we may be seeing just such a situation. The corporate earnings season, which is underway now, is clobbering expectations for the first quarter of 2021. We’ve seen reports from 121 S&P-listed companies, and so far earnings are up 45.3% year-over-year. Weighing in from Oppenheimer, chief investment strategist John Stoltzfus noted, “As the number of vaccines administered stateside has moved higher, business and consumer sentiment [have] broadly improved from the end of last year… for now the equity markets in our view reflect a continuing capitulation of a bearish overview of stocks and prospects for the economy that has overstayed its welcome among many investors… We continue to favor equities in the current transitional environment.” Taking Stoltzfus’s outlook into consideration, we wanted to take a closer look at two penny stocks scoring rave reviews from Oppenheimer. These tickers trading for less than $5 per share could gain over 100% in the next year, so say the firm’s analysts. Using TipRanks’ database, we found out what exactly makes both so compelling even with the risk involved with these plays. CASI Pharmaceuticals (CASI) The first penny stock we’re looking at is a pharmaceutical company with one foot in each of the world’s largest markets. CASI is based in both Beijing, China and Rockville, Maryland. The company is US in origin, with Chinese operations conducted by a wholly owned subsidiary. CASI has one drug available in the commercial market; Evomela has applications in both cell transplant procedures and the treatment of multiple myeloma, and has been available in China since 2019. In addition to Evomela, CASI has an active pipeline, featuring four drug candidates in various stages of development – from preclinical to Phase 1 or 2 trials. CASI’s pipeline focuses on hematological oncology, with drug candidates under investigation as treatments for non-Hodgkin’s Leukemia, multiple myeloma, and AML, as well as general solid tumor applications. CASI’s product line is designed for commercialization in the Chinese medical markets. CNTC19, CASI’s most advanced program, has received a Breakthrough Therapy Designation from China CDE, due to success shown by initial data in the Phase 1 study of safety and efficacy for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). The next step, a Phase 2 study for patients with B-cell non-Hodgkin Lymphoma, is currently enrolling. Also of note, CASI’s drug candidate BI-1206 showed potential after a Phase 1/2a trial. The company believes that the drug has potential to restore activity of rituximab in patients with non-Hodgkin lymphoma, already treated with rituximab, who have relapsed. Further trials are planned for later this year. On the financial end, CASI reported for full-year 2020 revenue of $15 million, compared to $4.1 million in 2019. This was based primarily on sales of Evomela, and exceeded the previously published guidance of $14 million for the year. The company finished 2020 with $57.1 million in cash on hand, and in March of this year, to raise capital, put over 15.8 million shares of common stock on the market. The stock sale grossed over $32 million before expenses. Covering CASI for Oppenheimer, analyst Leland Gershell believes that the recent financing “strengthens CASI’s position as the company continues to evaluate opportunities to further expand its portfolio of differentiated oncology assets.” The analyst added, “We believe CASI is one of a few publicly traded biotech companies positioned to achieve success by targeting the burgeoning Chinese pharmaceutical market. Through a licensing-driven business model, the company continues to build an oncology-focused portfolio of drug assets at all stages of development. Evomela is expected to grow 50%+ in 2021 and we believe the company’s CD19 CAR-T therapy for B-cell malignancies will become the preferred option in China within this competitive class.” In line with this bullish outlook, Gershell puts an Outperform (i.e. Buy) rating on the stock, and his $5 price target implies an upside of 192% for the next 12 months. (To view Gershell’s track record, click here) In general, the rest of the Street has an optimistic view of CASI. The stock’s Strong Buy status comes from the 3 Buys issued over the previous three months. The stock is selling for $1.70 per share, and its average price target of $4.10 suggests it has room for ~140% growth in 2021. (See CASI stock analysis on TipRanks) Vascular Biogenics (VBLT) Shifting focus slightly, from China to the US, we’ll look at Vascular Biogenics, a biopharma company developing treatments for both cancer and immune/inflammatory diseases. VBLT’s leading drug candidate is VB-111, an oncology drug being investigated as a treatment for multiple solid tumors. This first-in-class gene therapy has applications for ovarian cancer, recurrent glioblastoma, colon cancer, and thyroid cancer. In a Phase 1 trial, VB-111 was shown to be well-tolerated by over 300 cancer patients across those conditions. Further successful trials included Phase 2 studies that were tumor-specific for ovarian cancer, thyroid cancer, and recurrent glioblastoma. The drug candidate is currently undergoing a Phase 3 study, OVAL, for platinum-resistant Ovarian Cancer. That study has enrolled over 200 patients, and shows high response rates in over 50% of the evaluable patients. The next most advanced candidate, VB-201, in January of this year began dosing patients in a Phase 2 study. This randomized controlled study will investigate VB-201 as a treatment for COVID-19. Biopharmas require funds for continued research, and Vascular Biogenetics reported finishing 2020 with $30.8 million in cash, cash equivalents, and short-term bank deposits available. In a move to increase available funds, the company made a public offering of 6.9 million shares of common stock in April. At closing, the offering had raised over $28.3 million gross capital. After deducting expenses, the company will use the proceeds to fund continuing operations. Oppenheimer’s 5-star analyst Kevin DeGeeter is bullish on VBLT, especially with the OVAL study proceeding “on track.” “Phase III OVAL study of VB-111 for treatment of platinum-resistant ovarian cancer demonstrates improvement in ORR in second interim analysis that translates into an overall survival benefit. The company’s prior investment in commercial-scale manufacturing allows VBLT to secure attractive partnering/takeover economics despite the relatively modest size of the advanced ovarian cancer market,” DeGeeter opined. The analyst added, “Our differentiated outlook for VBLT is based in large measure on potential to engage FDA regarding regulatory filing based on PFS in 2H22 vs. primary endpoint of OS (2H23). We view 6-plus months of PFS as a successful outcome. Based on a disappointing update for Mersana’s XMT-1536 in January, we now view VB-111 as well positioned to be potential new SOC in r/r platinum-resistant ovarian cancer patients that have also failed prior Avastin therapy.” To this end, DeGeeter rates VBLT an Outperform (i.e. Buy), and sets a $5 price target that suggests the stock will grow 163% from the current share price of $1.91. (To view DeGeeter’s track record, click here) DeGeeter’s colleagues are also pounding the table on VBLT. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. With an average price target of $5 – matching DeGeeter’s above – VBLT shows room for a robust upside in the next 12 months. (See VBLT stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Rockville , Maryland , United-states , Beijing , China , Chinese , Kevin-degeeter , John-kennedy , John-stoltzfus , Leland-gershell , Stocks-could-rally-over

3 "Strong Buy" Momentum Stocks With More Room to Run

3 "Strong Buy" Momentum Stocks With More Room to Run
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

China , Netherlands , John-mcnulty , Didier-scemama , Samsung , Asml-holding , Installed-base , Strong-buy , Tiprank-best-stocks , சீனா , நெதர்லாந்து , ஜான்-மக்நல்டீ

Qualcomm: Too Much Risk Going Forward, Says Analyst

Qualcomm: Too Much Risk Going Forward, Says Analyst
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Tiprank-best-stocks , Christopher-rolland , Ualcomm , Emiconductor-industry , Usquehanna , கிறிஸ்டோபர்-ரோலண்ட் ,

Analysts Say 'Buy the Pullback' in These 3 Stocks

Analysts Say 'Buy the Pullback' in These 3 Stocks
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Mark-palmer , Deutsche-bank , Nielsen-holdings , Pullback-provides-attractive-entry-point , Wall-street , Moderate-buy , Old-house , Roku-originals , Jeffrey-rand , Advanced-video-advertising , Tiprank-best-stocks , குறி-பாமர்

Raymond James: 2 Chip Giants to Buy Now (And 1 to Avoid)

Semiconductors are one of the modern world’s essential industries, making possible so much of what we rely on or take for granted: internet access, high-speed computers with high-speed memory, even the thermostats that control our air conditioning – there isn’t much, tech-wise, that doesn’t use semiconductor chips. The global semiconductor chip market was valued at over $513 billion in 2019, and despite the worst the pandemic could do, the chip sector rose to $726 billion in 2020. It’s a market based on a near-limitless customer base; it’s estimated that 2.5 billion people own at least one smartphone. That’s 1 in 3 of the total world population, enough to ensure that demand for semiconductor chips will never slacken. And with that background, Raymond James analyst Chris Caso sees two chip giant poised to make gains this year – but one that investors should avoid. Let's take a closer look. Advanced Micro Devices (AMD) The first chip stock we’ll look at, AMD, is consistently ranked among the top 20 largest chip makers – by sales – globally. The company held the fifteenth spot last year, with $9.76 billion in total revenues. That top line was up 45% from 2019, when AMD was ranked eighteenth. AMD’s position in the industry is based on its high-quality products, including microprocessors, motherboard chipsets, and graphics processors. AMD’s Ryzen Mobile 4000 chip was the first 7nm x86 processor on the market. The chip company showed a solid second half in 2020, with revenues in Q3 and Q4 rapidly recovering the 1H20 dip and rising above 2019 level. Earnings in Q4 skyrocketed, growing from Q3’s 32 cents per share to an impressive $1.45 per share. For all of 2020, earnings came in at $2.06, compared to 30 cents for 2019. The strong second half pushed the full-year revenue to a company record, on the strength of expanding demand in the PC, gaming, and data center markets. AMD’s prospects have attracted Raymond James’ Chris Caso, who compares the company favorably to competitor Intel. “We are using the pullback since the start of the year to get involved with AMD, which we expect to be a secular winner due to what we believe to be a durable technical advantage vs. Intel. We think the stock’s pullback has been driven by improved sentiment that Intel will solve their manufacturing challenges, which will reverse AMD’s successes. We’re taking the other side of that view," the 5-star analyst noted. Caso continued, "Nowthat Intel has committed to internal manufacturing, we think it’s unlikely that Intel ever regains a transistor advantage vs. AMD, and the current roadmaps ensure an advantage for AMD/TSMC through at least 2024. In the meantime, we think Street numbers are too low for both server and consoles, putting our base case 2022 EPS estimate of $2.81 12% ahead of the Street, with an upside case to about $3.00." In line with this outlook, Caso initiated coverage of AMD with an Outperform (i.e. Buy) rating, and $100 price target to suggest a 23% one-year upside potential. (To watch Caso’s track record, click here) The Raymond James view is no bullish outlier; AMD has 13 positive reviews on record. These are partly balanced by 5 Holds and 1 Sell, making the analyst consensus rating a Moderate Buy. The share are selling for $81.11, and their $104.44 average price target implies an upside of ~29% for the next 12 months. (See AMD stock analysis on TipRanks) Nvidia Corporation (NVDA) Next up, Nvidia, is another of the chip industry’s giants. Like AMD, Nvidia is slowly rising in the rankings; going by total sales, the company was rated number 10 in 2019 – and number 8 in 2020. Nvidia’s sales last year totaled more than $16 billion, a gain of 53% year-over-year. Nvidia rode to its success on the combination of memory chips – which have a strong market in the data center segment – and graphics processors – which are popular among both hardcore gamers and professional graphic designers. For the most recent quarter, Q4 of fiscal 2021, ending on December 31, Nvidia reported $5 billion in revenue, a company record, and a 61% gain from the year before. EPS rose from $1.53 in the prior Q4 to $2.31 in the current print, a gain of 51%. Full year numbers were strong; the $16.68 billion at the top line was a record, and the EPS, at $6.90, was 53% higher than the previous year. Company management noted the strength of the data center segment, but also pointed out that Nvidia has a growing AI business. The company makes between 5% and 10% of its total sales in the automotive market, and more than half of that is AI-related, in the autonomous vehicle niche. Raymond James’ Chris Caso notes this, too, in his report upgrading his stance on NVDA. “Our call is not really new, as we’ve been positive on NVDA for some time. Our call rather is meant to express our conviction in both the short and long term. In the short term, we think NVDA results will be more dependent on supply than demand given widespread shortages – and we do expect incremental supply as the year progresses…. Our longer term conviction is driven by the fact that NVDA has more shots on goal than anyone else in our coverage, and their success in AI has earned them a permanent seat at the table in both hyperscale and enterprise compute,” Caso opined. Caso bumps his stance up from Outperform to Strong Buy, and sets a price target of $750. At current levels, this indicates room for a 17% one-year upside. NVDA’s strong share appreciation over the past 12 months (115%) has pushed the stock price close to the average price target. Shares are selling for $614.47, with an average target of $670.20 suggesting room for 9% growth. Nonetheless, the stock holds a Strong Buy consensus rating based on 22 Buys and 4 Hold given in recent weeks. (See NVDA stock analysis on TipRanks) Intel Corporation (INTC) The third stock we’re looking at, Intel, is the one that Raymond James says to avoid. This may seem counterintuitive; Intel is, by sales, the world’s largest semiconductor chip maker, with more than $77 billion in annual revenue last year and a leading position in a $720+ billion market. So why does Caso advise caution here? “Intel’s stock has risen of late due to optimism that new leadership from their very capable new CEO will allow them to turn around their manufacturing issues and return to their former dominance. Our Underperform rating reflects not just the risk that Intel won’t reach that goal, but also the pain they will likely endure in pursuit of that goal in terms of capex, lost market share, and a shifting landscape in datacenter that will make the industry less dependent on Intel," Caso explained. The analyst added, "In addition, we’re concerned that demand in the PC market, on which Intel remains highly dependent, has been significantly pulled forward due to the pandemic, and expect an eventual mean reversion – which may unfortunately occur just as Intel needs to ramp investment.” Caso, as noted, rates INTC an Underperform (i.e. Sell), and does not put a price target on it. All in all, the market’s current view on INTC is a mixed bag, indicating uncertainty as to its prospects. The stock has a Hold analyst consensus rating based on 12 Buys, 10 Holds, and 8 Sells. Meanwhile, the $67.68 price target suggests a modest upside potential of nearly 6%. (See INTC stock analysis on TipRanks) To find good chip ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Raymond-jame-chris-caso , Raymond-james , Intel-corporation , Nvidia-corporation , Nvidia , Intel , Jame-chris-caso , Strong-buy , Tiprank-best-stocks , Aymond-james , Hris-caso , Emiconductor-chip

Peloton: Tread+ Warning Nothing More Than a 'PR Black Eye,' Says Analyst

Peloton: Tread+ Warning Nothing More Than a 'PR Black Eye,' Says Analyst
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Tiprank-best-stocks ,

GameStop: Overvalued and Vulnerable to the Digital Threat

Although we are only over one quarter into 2021, it will be interesting to see if any other story tops the GameStop (GME) short squeeze mania this year. The struggling video game retailer has provided no end of headlines in 2021 after retailers re-wrote the stock market rulebook. That said, the mighty gains – up by 721% year-to-date even after pulling back by 55% from the January madness highs – have caused a huge chasm between fundamentals and valuation. Accordingly, Ascendiant’s Edward Woo believes that over the long run GameStop’s “current elevated share prices will come back down to match its current weak results and outlook.” That said, Woo expects the company to benefit from new video game consoles sales from Sony and Microsoft. The new PlayStation and Xbox consoles, respectively, were launched in November and so far, sales have been “very strong.” As it is still the early phase of the new console launches, Woo says GameStop anticipates “continued strong growth over the next year.” Woo also thinks the arrival of Chewy co-founder Ryan Cohen who joined GameStop’s board in January and has been behind the effort to transition to a more e-commerce centric approach has helped fuel the rally. However, GameStop is faced with a threat it will find very difficult to counter: the continuous rise of digital sales. Even with the pivot toward e-commerce, Woo thinks it will be hard for GameStop to compete. “Recent reports by the video game publishers shows that digital revenue is increasing at a fast pace (~90% or more of publishers’ revenues),”, so concerns are increasing that digital game sales (which GameStop has very low market share) is beginning to be a bigger factor (~70% of a game’s total sales are now full game digital downloads),” Woo said. “We remain very concerned about the long-term prospects for its video game business especially once hardware sales temper as the installed base matures.” With this in mind, Woo rates GME shares a Sell, along with a $10 price target. The implication for investors? A very painful 93% drop. (To view Woo’s track record, click here) The rest of the Street’s take is hardly more reassuring. Shares are expected to be changing hands for a 65% discount a year from now, given the average piece target stands at $53.80. Based on 2 Holds vs. 4 Sells, the analyst consensus rates GME stock a Moderate Sell. (See GME stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Ryan-cohen , Sony , Gamestop , Microsoft , Tiprank-best-stocks , Dward-woo , Ideo-game-publishers , Me-stock , Ideo-game-consoles , ரியான்-கோஹன் , சோனி , கேம்ஸ்டாப்

The Valuation on NovoCure Stock Is a Tough Pill to Swallow, Says Analyst

The Valuation on NovoCure Stock Is a Tough Pill to Swallow, Says Analyst
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Tiprank-best-stocks ,

Riot Blockchain: Recent Developments Keep Up Momentum

Riot Blockchain: Recent Developments Keep Up Momentum
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Tiprank-best-stocks ,

Amarin: Could the New CEO Help Vazkepa's European Push?

Amarin: Could the New CEO Help Vazkepa's European Push?
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Tiprank-best-stocks ,